Szemészet, 2011 (148. évfolyam, 1-4. szám)

2011-12-01 / 2. szám

Szemészet

27. Kabbaj N., Sentissi S., Mohammadi M., Benaissa A., Amrani N.: Anterior ischemic optic neuropathy complicating interferon alpha and ribavirin therapy in patients with chronic hepatitis C. Gastroenterol Clin Biol 2009; 33:115-117.

28. Kado M., Yoshida A., Sakagami S.: Retinopathy in patients with type C hepatitis during interferon therapy. J Jpn Ophtalmol Assoc (Nippon-no-Ganka)1993; 64: 961-965.

29. Kawano J., Lam W.C., Waheeba S., Thaib Q., Heathcoteb J.: Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 1171-1173.

30. Kirchhoff A., Kirchhoff U., Lafrenz M„ Guthoff R.: Bilateral AION after the combined therapy of hepatitis C with PEG-interferon alpha2B and ribavirin (in German). Klin Monbl Augenheilkd 2004; 221: 791-793.

31. Kiuchi K., Kitagawa C, Miyashiro M.: Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon. Nippon Ganka Gakkai Zasshi 2009; 113: 16-23.

32. Kreutzer К., Bonnekoh В., Franke I., Ulrich J., Gollnick H.: Sarcoidosis, myasthenia gravis and anterior ischemic optic neuropathy: severe side effects of adjuvant interferon-alpha-therapy in malignant melanoma (in German). J Dtsch Dermatol Ges 2004; 2: 689-694.

33. Lohmann C.P., Kroher G., Bogenrieder T, Spiegel D., Preuner J.: Severe loss of vision during adjuvant interferon alpha-2b treatment for malignant melanoma (letter). Ancet 1999; 353: 1326.

34. Louis d’Alterochea, S. Majzoubb, Lecuyer A.I., Delplace M-R, Bacq Y.: Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61.

35. Miscerachs-Garcia S., Mesa-Toledo E., Arruga-Ginebreda J., Castillo-Campillo L.: Ischemic neuroretinopathy associated with use of interferon. Arch Soc Esp Oftalmol 2005; 80: 533-535.

36. Nakamura A., Saitoh M., Mitsudome X, Kuroki K., Sawada A.: Sudden visual impairment in a case under interferon for type C chronic active hepatitis. J Rev Clin Ophtalmol (Ganka Rinsho Iho) 1995; 89: 1386-1389.

37. Nao-i N., Matuura Y., Sawada A.: Prospective study of the incidence of interferon-induced retinopathy in patients with chronic hepatitis. Ophtalmology 1994; 101: 119.

38. Nishiguchi S., Shiomi S., Enomoto M., Lee C., Jomura H., Tamori A., Habu D., Takeda T., Yanagihara N., Shiraki K.: Does ascorbic acid prevent retinopathy during interferon therapy in patients with chronic hepatitis C? Gastroenterol 2001; 36: 486-4891.

39. Norcia E, Di Maria A., Prandini F., Redaelli C.: Natural interferon therapy: optic nerve ischemic damage? Ophtalmologica 1999; 213: 339-340.

40. Ogata H., Suzuki H., Shimizu, Shimizu K., Ishikawa H., Izumi N., Kurosaki M.: Pegylated Interferon-Associated Retinopathy in Chronic Hepatitis C Patients. Jpn J Ophthalmol 2006; 50: 293-295.

4L Ischemic Optic Neuropathy Decompression Trial Research Group: Ischemic optic neuropathy decompression trial. Twenty-four-month update. Arch Ophthalmol 2000; 118: 793-797.

42. Perlemuter G., Bodaghi B., Le Hoang R, Izem C., Buffet C., Wechsler В., Piette J.C., Cacoub R: Visual loss during interferon-alpha therapy in hepatitis C virus infection (letter). J Hepatol 2002; 37: 701-704.

43. Purvin V.A.: Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995; 113: 1041-1044.

44. Rodney AJ., Gombos D.S., Pagliaro L.C., Tannir N.M.: Ischemic optic neuropathy associated with low-dose interferon-alpha: report of two cases. Am J Gastroenterol 2001; 96: 1303-1304.

45. Sauer A., Lenoble R, Bader R, Speeg-Schatz C., Bourcier T., Nasica X.: Ocular complications of hepatitis C treatment (in French). J Fr Ophtalmol 2007; 30: e20.

46. Sené D., Touitou V, Bodaghi B., Saadoun D., Perlemuter G., Cassoux N., Piette J.C., Hoang P.L., Cacoub R: Intraocular complications of INF-a and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13: 3137-3140.

47. Shahidullah A.B., Cerulli M.A., Berman D.H.: Interferon may cause retinopathy during hepatitis therapy. Am J Gastroenterol 1995; 90: 1543.

48. Stoffeins B.M.: Interferon causes ischemic ocular diseases-case studies and review of the literature. Hin Monbl Augenheilkd 2006; 223: 367-371.

49. Sugano S., Yanagimoto M., Suzuki T, Sato M., Onmura H., Aizawa H., Makino H.: Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy forr chronic active hepatitis C. Am J Gastroenterol 1994; 89: 2054-2056.

50. Tadokoro Y., Ohtsuki H., Okano M., Furuse T: A case of disc edema during systemic interferon therapy. Folia Ophthalmol Jpn (Ganka-Kiyo) 1995; 46: 653-656.

51. Tokai R., Ikeda T, Miyaura T, Sato K.: Interferon-Associated Retinopathy and Cystoid Macular Edema. Arch Ophthalmol 2001; 119: 1077-1079.

52. Tóth J., Fejes G., Csizmazia E.: A hipertónia progressziójának szemészeti követése. Magyar Orvos 2008; 45-48.

53. Vardizer Y., Linhart Y., Loewenstein A., Garzozi H., Mazawi N., Kesler A.: Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 2003; 23: 256-259.

54. Wei Y.H., Wang I.H., Woung L.C., Jou J.R.: Anterior Ischemic Optic Neuropathy Associated with Pegylated Interferon Therapy for Chronic Hepatitis C. Ocul Immunol Inflamm 2009; 17: 191-194.

55. Willson R.A.: Visual Side Effects of Pegylated Interferon During Therapy for Chronic Hepatitis C Infection. J Clin Gastroenterol 2004; 38: 717-722.

56. Yoshitoshi T, Saegusa K., Watanabe A., et al.: A case of panophthalmitis developed during interferon therapy. Jpn J Clin Ophthalmol (Rinsho Ganka) 1994; 48: 692-693.

57. Zegans M.E., Anninger W, Chapman C., Gordon S.R.: Ocular manifestations of hepatitis C virus infection. Ophthalmology 2002; 13: 423-427.

Levelezési cím; Dr. Horváth Éva Semmelweis Egyetem, Szemészeti Klinika 1085 Budapest, Mária u. 39. E-mail: eva.horvath01@gmail.com